胰神经内分泌瘤（panNETs）是多发性内分泌肿瘤1型（MEN1）患者死亡的主要原因。最近尚未建立索马托斯顿受体正电子发射计算机断层扫描（SSTR PET / CT）在MEN1中的作用。本次研究的目的是在实际情况下评估MEN1的胰腺成像情况。58位MEN1患者（中位年龄40岁（范围16-72岁））接受了SSTR PET / CT成像，其中47位患者被作为筛查工具进行成像，无论疾病阶段如何，另外11例病人接受该成像用于进一步确定已知的panNETs。SSTR PET / CT和匹配传统成像进行盲分析。我们在47个月的中位随访期间评估了发现和SSTR PET / CT的影响。SSTR PET / CT检测到的panNETs是传统成像的三倍（p <0.001）。 SSTR PET / CT改变了27名患者（47％）的管理。有7名患者（12％）接受手术治疗，5名患者（9％）接受了全身治疗。在25名先前没有panNET（n = 22）或手术治疗后缓解的患者中（n = 3），SSTR PET / CT确定了panNET（n = 14）或复发（n = 1）的情况，共60％的病人。在八名患者中，SSTR PET / CT揭示了一个在传统成像上不能立即看到的panNET。在47个月的中位随访期间，有三个在传统成像中变得可见，但没有需要干预。当SSTR PET / CT为阴性时，无法在38个月的随访期内在常规成像上发现panNET。 SSTR PET / CT在检测panNETs方面表现出高准确性，并且改变了近一半MEN1患者的临床管理。 SSTR PET / CT使得MEN1相关panNETs的及时诊断和分期成为可能。 © The Author（s）2023。由牛津大学出版社代表（ESE）欧洲内分泌学会出版。

Pancreatic neuroendocrine tumors (panNETs) are the leading cause of death in patients with multiple endocrine neoplasia type 1 (MEN1). The role of somatostatin receptor positron emission tomography (SSTR PET/CT) in MEN1 has not been established. The aim was to assess pancreatic imaging in MEN1 in a real-life setting.Fifty-eight patients with MEN1 (median age 40 (range 16-72) years) underwent SSTR PET/CT imaging; either as a screening tool regardless of disease stage (n = 47) or to further characterize known panNETs (n = 11). SSTR PET/CT and matched conventional imaging were blindly analyzed. We assessed the findings and the impact of SSTR PET/CT during a median follow-up of 47 months.SSTR PET/CT detected three times as many panNETs as conventional imaging (p < 0.001). SSTR PET/CT altered the management of 27 patients (47%). Seven patients (12%) were referred for surgery, and five (9%) received systemic treatment. In 15/25 (60%) patients with no previous panNET (n = 22) or in remission after surgery (n = 3), SSTR PET/CT identified a panNET (n = 14) or recurrence (n = 1). In eight patients, SSTR PET/CT revealed a panNET not immediately visible on conventional imaging. During a median follow-up of 47 months, three became visible on conventional imaging, but none required intervention. When SSTR PET/CT was negative, no panNETs were identified on conventional imaging during 38 months of follow-up.SSTR PET/CT demonstrates high accuracy in the detection of panNETs and alters the clinical management in nearly half of the MEN1-patients. SSTR PET/CT enables timely diagnosis and staging of MEN1-related panNETs.© The Author(s) 2023. Published by Oxford University Press on behalf of (ESE) European Society of Endocrinology.